Evidence map›Paper›PMID 32406992›Full record

ReviewSmall (Weinheim an der Bergstrasse, Germany)2020

Safety Considerations of Cancer Nanomedicine-A Key Step toward Translation.

Xiangsheng Liu, Ivanna Tang, Zev A Wainberg, Huan Meng

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Small (Weinheim an der Bergstrasse, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. The Immune Microenvironment in Liver Cancer: From Analysis to Targeting.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xiangsheng LiuDivision of NanoMedicine, Department of Medicine, University of California, Los Angeles, CA, 90095, USA.ORCID 0000-0002-5719-2838
Ivanna TangDivision of NanoMedicine, Department of Medicine, University of California, Los Angeles, CA, 90095, USA.
Zev A WainbergDivision of Hematology Oncology, Department of Medicine, University of California, Los Angeles, CA, 90095, USA.
Huan MengDivision of NanoMedicine, Department of Medicine, University of California, Los Angeles, CA, 90095, USA.ORCID 0000-0001-8844-3938

Funding

UCLA Multifunctional Mesoporous Silica Nanoparticle Platform for Treatment of Pancreas CancerU01CA198846 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DONAHUE, TIMOTHY R, MENG, HUAN · 2015 to 2019
$2.4M
NCI NIH HHS U01 CA198846
6 · The paper itself

Abstract

The rate of translational effort of nanomedicine requires strategic planning of nanosafety research in order to enable clinical trials and safe use of nanomedicine in patients. Herein, the experiences that have emerged based on the safety data of classic liposomal formulations in the space of oncology are discussed, along with a description of the new challenges that need to be addressed according to the rapid expansion of nanomedicine platform beyond liposomes. It is valuable to consider the combined use of predictive toxicological assessment supported by deliberate investigation on aspects such as absorption, distribution, metabolism, and excretion (ADME) and toxicokinetic profiles, the risk that may be introduced during nanomanufacture, unique nanomaterials properties, and nonobvious nanosafety endpoints, for example. These efforts will allow the generation of investigational new drug-enabling safety data that can be incorporated into a rational infrastructure for regulatory decision-making. Since the safety assessment relates to nanomaterials, the investigation should cover the important physicochemical properties of the material that may lead to hazards when the nanomedicine product is utilized in humans.

Indexed as

NanomedicineNeoplasmsToxicologyAntineoplastic AgentsDrug and Narcotic ControlHumansNanostructuresAntineoplastic Agentsclinical trialsnano safetysafe-by-designtranslational nanomedicine

Identifiers

PMID32406992
PMCPMC7486239

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.